Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin and erythropoiesis in type 2 diabetic kidney disease
ChiCTR2400089448Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of canagliflozin in diabetic glomerulosclerosis and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoints: Blood routine examination, Erythropoietin and 1 more. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
canagliflozin
03
Conditions
diabetic glomerulosclerosistype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400089448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089448.